| Name | BRIGHT MINDS BIOSCIENCES INC. |
|---|---|
| CIK | 0001827401 |
| Tickers | DRUG |
| Exchanges | Nasdaq |
| Entity type | other |
| Category | <br>Emerging growth company |
| SIC | 2834 Pharmaceutical Preparations |
| EIN | 000000000 |
| LEI | — |
| Fiscal year end | 0930 |
| State of incorporation | A1 British Columbia, Canada |
| Phone | 6474072515 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
No Financialist filing articles yet for this CIK.
182 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001172661-26-005294 | 005-94288 | 261559145 | 34 | 10112 | |||
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001213900-26-120152 | 005-94288 | 261555522 | 34 | 13699 | |||
| 2026-11-02 | 6-K | f6k-20261102drug.htm | 0002060755-26-000063 | 001-40997 | 261512825 | 34 | 25368 | |||
| 2026-10-02 | 6-K | FORM 6-K | 0001062993-26-005170 | 001-40997 | 261437847 | 34 | 22191 | |||
| 2026-10-01 | 6-K | FORM 6-K | 0001062993-26-005123 | 001-40997 | 261428478 | 34 | 23739 | |||
| 2026-08-17 | 6-K | FORM 6-K | 0001062993-26-004442 | 001-40997 | 261284198 | 34 | 817494 | |||
| 2026-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001172661-26-003688 | 005-94288 | 261279671 | 34 | 10076 | |||
| 2026-08-13 | S-8 | FORM S-8 | 0001062993-26-004235 | 333-298286 | 261269542 | 33 | 488373 | 1 | 1 | |
| 2026-08-12 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000919574-26-004968 | 005-94288 | 261266229 | 34 | 12555 | |||
| 2026-07-02 | SCHEDULE 13D/A | xslSCHEDULE_13D_X02/primary_doc.xml | 0001062993-26-003506 | 005-94288 | 261153125 | 34 | 14277 | |||
| 2026-06-03 | 6-K | FORM 6-K | 0001062993-26-003005 | 001-40997 | 261058781 | 34 | 4259018 | |||
| 2026-06-02 | 6-K | FORM 6-K | 0001062993-26-002975 | 001-40997 | 261054329 | 34 | 12473 | |||
| 2026-05-28 | 6-K | f6k-20260526.htm | 0002060755-26-000031 | 001-40997 | 261028156 | 34 | 12291 | |||
| 2026-05-20 | 6-K | FORM 6-K | 0001062993-26-002801 | 001-40997 | 261000763 | 34 | 822459 | |||
| 2026-05-15 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000902664-26-002546 | 005-94288 | 26989530 | 34 | 15161 | |||
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001274173-26-000135 | 005-94288 | 26984893 | 34 | 12348 | |||
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001274173-26-000134 | 005-94288 | 26984890 | 34 | 12348 | |||
| 2026-05-12 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001213900-26-055371 | 005-94288 | 26970629 | 34 | 13603 | |||
| 2026-04-30 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000929638-26-001709 | 005-94288 | 26925303 | 34 | 9801 | |||
| 2026-04-30 | 4 | xslF345X06/form4.xml | 0000929638-26-001708 | 8887 | ||||||
| 2026-02-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001274173-26-000081 | 005-94288 | 26642339 | 34 | 12268 | |||
| 2026-02-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001831942-26-000007 | 005-94288 | 26641846 | 34 | 11515 | |||
| 2026-02-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001193125-26-054519 | 005-94288 | 26640549 | 34 | 10680 | |||
| 2026-02-13 | 6-K | FORM 6-K | 0001062993-26-000881 | 001-40997 | 26628689 | 34 | 827500 | |||
| 2026-02-06 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001172661-26-000518 | 005-94288 | 26607151 | 34 | 10708 | |||
| 2026-01-09 | 6-K | FORM 6-K | 0001062993-26-000151 | 001-40997 | 26523210 | 34 | 22672 | |||
| 2026-01-09 | 6-K | FORM 6-K | 0001062993-26-000138 | 001-40997 | 26521051 | 34 | 267696 | |||
| 2026-01-09 | 424B5 | FORM 424B5 | 0001062993-26-000136 | 333-289851 | 26521021 | 33 | 401953 | |||
| 2026-01-08 | 6-K | f6k20260107.htm | 0002060755-26-000009 | 001-40997 | 26517201 | 34 | 26921 | |||
| 2026-01-07 | 6-K | FORM 6-K | 0001062993-26-000102 | 001-40997 | 26516664 | 34 | 5986 | |||
| 2026-01-07 | FWP | FORM FWP | 0001062993-26-000098 | 333-289851 | 26515427 | 34 | 4877850 | |||
| 2026-01-07 | FWP | FORM FWP | 0001062993-26-000090 | 333-289851 | 26513842 | 34 | 4876184 | |||
| 2026-01-07 | 424B5 | FORM 424B5 | 0001062993-26-000089 | 333-289851 | 26513840 | 33 | 430298 | |||
| 2026-01-07 | 6-K | f6k20260106launch.htm | 0002060755-26-000007 | 001-40997 | 26513553 | 34 | 25788 | |||
| 2026-01-06 | 6-K | f6k20260106nr.htm | 0002060755-26-000005 | 001-40997 | 26512871 | 34 | 30373 | |||
| 2026-01-05 | 6-K | f6k-20260105.htm | 0002060755-26-000002 | 001-40997 | 26507915 | 34 | 12601 | |||
| 2025-12-23 | F-X | FORM F-X | 0001437749-25-038731 | 001-40997 | 251601841 | 33 | 36059 | |||
| 2025-12-23 | 40-F | FORM 40-F | 0001437749-25-038729 | 001-40997 | 251601838 | 34 | 9093645 | 1 | 1 | |
| 2025-11-17 | 6-K | FORM 6-K | 0001062993-25-016913 | 001-40997 | 251491900 | 34 | 33953 | |||
| 2025-11-17 | 6-K/A | FORM 6-K/A | 0001062993-25-016909 | 001-40997 | 251490955 | 34 | 43915 | |||
| 2025-11-14 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001213900-25-111137 | 005-94288 | 251488745 | 34 | 21070 | |||
| 2025-11-13 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-25-004874 | 005-94288 | 251475699 | 34 | 15494 | |||
| 2025-11-12 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001214659-25-016262 | 005-94288 | 251469027 | 34 | 9469 | |||
| 2025-11-07 | 6-K | FORM 6-K | 0001062993-25-016559 | 001-40997 | 251463113 | 34 | 12801 | |||
| 2025-11-07 | 6-K | FORM 6-K | 0001062993-25-016557 | 001-40997 | 251462870 | 34 | 34677 | |||
| 2025-09-05 | 6-K | f6k-20250904.htm | 0002060755-25-000036 | 001-40997 | 251294682 | 34 | 17408 | |||
| 2025-09-02 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-25-002807 | 333-289851 | 251287651 | 33 | 1712 | ||
| 2025-08-28 | CORRESP | filename1.htm | 0001062993-25-015036 | 26625 | ||||||
| 2025-08-27 | UPLOAD | filename1.pdf | 0000000000-25-009199 | 333-289851 | 40023 | |||||
| 2025-08-26 | F-3 | FORM F-3 | 0001062993-25-014903 | 333-289851 | 251252268 | 33 | 821338 | 1 | 1 | |
| 2025-08-15 | 6-K | FORM 6-K | 0001062993-25-014464 | 001-40997 | 251221754 | 34 | 787219 | |||
| 2025-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001274173-25-000208 | 005-94288 | 251215567 | 34 | 10587 | |||
| 2025-08-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001214659-25-011955 | 005-94288 | 251210506 | 34 | 9398 | |||
| 2025-08-11 | 6-K | FORM 6-K | 0001062993-25-014005 | 001-40997 | 251199919 | 34 | 765883 | |||
| 2025-05-28 | 6-K | f6k-20250528.htm | 0001183740-25-000037 | 001-40997 | 25995183 | 34 | 11204 | |||
| 2025-05-21 | 6-K | f6k-20250520.htm | 0002060755-25-000016 | 001-40997 | 25970567 | 34 | 23092 | |||
| 2025-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001415889-25-013183 | 005-94288 | 25954889 | 34 | 18768 | |||
| 2025-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000950170-25-072739 | 005-94288 | 25954094 | 34 | 10310 | |||
| 2025-05-14 | 6-K | f6k-20250513.htm | 0002060755-25-000012 | 001-40997 | 25942078 | 34 | 23039 | |||
| 2025-04-29 | 6-K | f6k-20250428.htm | 0001183740-25-000033 | 001-40997 | 25882149 | 34 | 19675 | |||
| 2025-04-08 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001214659-25-005583 | 005-94288 | 25821592 | 34 | 9283 | |||
| 2025-04-07 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001274173-25-000106 | 005-94288 | 25818204 | 34 | 10586 | |||
| 2025-03-05 | 6-K | f6k-20250304.htm | 0001183740-25-000029 | 001-40997 | 25707626 | 34 | 29135 | |||
| 2025-02-24 | 6-K | f6k-20250224.htm | 0001183740-25-000026 | 001-40997 | 25655391 | 34 | 10881 | |||
| 2025-02-14 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-25-000478 | 333-284694 | 25632359 | 33 | 1718 | ||
| 2025-02-14 | 424B3 | FORM 424B3 | 0001062993-25-002569 | 333-284694 | 25630209 | 33 | 206119 | |||
| 2025-02-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-25-001021 | 005-94288 | 25628435 | 34 | 11854 | |||
| 2025-02-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001493152-25-006845 | 005-94288 | 25628324 | 34 | 9235 | |||
| 2025-02-14 | 6-K | FORM 6-K | 0001062993-25-002353 | 001-40997 | 25622295 | 34 | 719043 | |||
| 2025-02-12 | CORRESP | filename1.htm | 0001062993-25-002152 | 25495 | ||||||
| 2025-02-11 | UPLOAD | filename1.pdf | 0000000000-25-001502 | 333-284694 | 39987 | |||||
| 2025-02-10 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001214659-25-002303 | 005-94288 | 25604789 | 34 | 9283 | |||
| 2025-02-07 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001274173-25-000016 | 005-94288 | 25599950 | 34 | 10444 | |||
| 2025-02-05 | F-3 | FORM F-3 | 0001062993-25-001662 | 333-284694 | 25590699 | 33 | 580258 | |||
| 2025-01-08 | 6-K | f6k-20250107im.htm | 0001183740-25-000008 | 001-40997 | 25516120 | 34 | 18975 | |||
| 2024-12-31 | 20-F | FORM 20-F | 0001062993-24-021301 | 001-40997 | 241590899 | 34 | 8328391 | 1 | 1 | |
| 2024-11-21 | 6-K | FORM 6-K | 0001062993-24-019452 | 001-40997 | 241482949 | 34 | 19193 | |||
| 2024-11-19 | D | xslFormDX01/primary_doc.xml | 06b | 0001183740-24-000091 | 021-529842 | 241474914 | 33 | 9922 | ||
| 2024-11-12 | SC 13G | SC 13G | 0001104659-24-116794 | 005-94288 | 241448376 | 34 | 77044 | |||
| 2024-11-06 | 4 | xslF345X05/form4.xml | 0000929638-24-003752 | 6891 | ||||||
| 2024-11-06 | SC 13G/A | AMENDMENT NO. 1 | 0000929638-24-003750 | 005-94288 | 241430893 | 34 | 63926 | |||
| 2024-11-05 | SC 13D/A | FORM SC 13D/A | 0001062993-24-018312 | 005-94288 | 241427196 | 34 | 32979 | |||
| 2024-11-05 | SC 13D/A | FORM SC 13D/A | 0001062993-24-018310 | 005-94288 | 241427182 | 34 | 33491 | |||
| 2024-11-05 | 6-K | FORM 6-K | 0001062993-24-018274 | 001-40997 | 241425026 | 34 | 17371 | |||
| 2024-10-25 | SC 13G | formsc13g.htm | 0001493152-24-042515 | 005-94288 | 241397084 | 34 | 94390 | |||
| 2024-10-23 | SC 13G | drug13g.htm | 0000935836-24-000636 | 005-94288 | 241390216 | 34 | 61756 | |||
| 2024-10-23 | SC 13G | BRIGHT MINDS BIOSCIENCES INC. | 0000902664-24-005963 | 005-94288 | 241390205 | 34 | 70444 | |||
| 2024-10-22 | SC 13G | sc13g.htm | 0000929638-24-003553 | 005-94288 | 241386350 | 34 | 111450 | |||
| 2024-10-22 | SC 13G/A | SC 13G/A | 0001104659-24-110554 | 005-94288 | 241386342 | 34 | 124925 | |||
| 2024-10-22 | D | xslFormDX01/primary_doc.xml | 06b | 0001183740-24-000085 | 021-527406 | 241384486 | 33 | 10077 | ||
| 2024-10-21 | 6-K | f6k20241021.htm | 0001183740-24-000084 | 001-40997 | 241383412 | 34 | 19595 | |||
| 2024-10-18 | 6-K | f6k20241018.htm | 0001183740-24-000081 | 001-40997 | 241380742 | 34 | 20459 | |||
| 2024-10-17 | 4 | xslF345X05/form4.xml | 0000929638-24-003542 | 29577 | ||||||
| 2024-10-17 | 3 | xslF345X02/form3.xml | 0000929638-24-003540 | 7829 | ||||||
| 2024-10-16 | SC 13G | SC 13G | 0001193125-24-238029 | 005-94288 | 241374099 | 34 | 65494 | |||
| 2024-10-16 | 6-K | f6k-20241015.htm | 0001183740-24-000079 | 001-40997 | 241373829 | 34 | 14109 | |||
| 2024-10-16 | 6-K | FORM 6-K | 0001171843-24-005653 | 001-40997 | 241373815 | 34 | 12486 | |||
| 2024-10-03 | 6-K | FORM 6-K | 0001171843-24-005482 | 001-40997 | 241350410 | 34 | 14657 | |||
| 2024-09-12 | 6-K | f6k20240912.htm | 0001183740-24-000073 | 001-40997 | 241294436 | 34 | 23312 | |||
| 2024-08-15 | 6-K | FORM 6-K | 0001062993-24-015119 | 001-40997 | 241210400 | 34 | 711473 | |||
| 2024-05-17 | 6-K | FORM 6-K | 0001062993-24-010545 | 001-40997 | 24957360 | 34 | 709902 | |||
| 2024-05-17 | 6-K | FORM 6-K | 0001062993-24-010535 | 001-40997 | 24957324 | 34 | 911318 | |||
| 2024-05-03 | D | xslFormDX01/primary_doc.xml | 06b | 0001183740-24-000039 | 021-512284 | 24910351 | 33 | 11324 | ||
| 2024-02-26 | SC 13D/A | sc13da2-im.htm | 0001183740-24-000021 | 005-94288 | 24681444 | 34 | 35071 | |||
| 2024-02-26 | SC 13D/A | sc13da1-im.htm | 0001183740-24-000019 | 005-94288 | 24681408 | 34 | 34938 | |||
| 2024-02-13 | 6-K | FORM 6-K | 0001062993-24-002875 | 001-40997 | 24622394 | 34 | 702430 | |||
| 2024-01-18 | SC 13D | sch13d-im.htm | 0001183740-24-000006 | 005-94288 | 24540967 | 34 | 34043 | |||
| 2023-12-29 | 20-F | FORM 20-F | 0001062993-23-023281 | 001-40997 | 231528097 | 34 | 9140120 | 1 | 1 | |
| 2023-12-26 | 6-K | f6k20231222.htm | 0001183740-23-000134 | 001-40997 | 231511065 | 34 | 18752 | |||
| 2023-12-08 | 6-K | FORM 6-K | 0001062993-23-022132 | 001-40997 | 231473846 | 34 | 17166 | |||
| 2023-08-15 | 6-K | FORM 6-K | 0001062993-23-016456 | 001-40997 | 231172718 | 34 | 755857 | |||
| 2023-08-08 | 6-K | f6k20230808drug.htm | 0001183740-23-000098 | 001-40997 | 231151778 | 34 | 33063 | |||
| 2023-07-20 | 6-K | f6k20230719drug.htm | 0001183740-23-000090 | 001-40997 | 231099234 | 34 | 27424 | |||
| 2023-07-12 | 6-K | f6k.htm | 0001183740-23-000087 | 001-40997 | 231085173 | 34 | 18335 | |||
| 2023-06-22 | 6-K | f6k-20230622drug.htm | 0001183740-23-000077 | 001-40997 | 231033181 | 34 | 17826 | |||
| 2023-05-15 | 6-K | FORM 6-K | 0001062993-23-011135 | 001-40997 | 23924302 | 34 | 744304 | |||
| 2023-04-19 | 6-K | f6k-20230419drug.htm | 0001183740-23-000053 | 001-40997 | 23829950 | 34 | 20276 | |||
| 2023-04-10 | 6-K | FORM 6-K | 0001171843-23-002211 | 001-40997 | 23809736 | 34 | 14387 | |||
| 2023-03-02 | 6-K | f6k-20230301drug.htm | 0001183740-23-000039 | 001-40997 | 23698144 | 34 | 938063 | |||
| 2023-02-27 | 6-K | f6k-20230227drug.htm | 0001183740-23-000032 | 001-40997 | 23676686 | 34 | 33837 | |||
| 2023-02-17 | 6-K | f6k-20230217drug.htm | 0001183740-23-000027 | 001-40997 | 23641875 | 34 | 21301 | |||
| 2023-02-08 | 6-K | f6k-20230208drug.htm | 0001183740-23-000024 | 001-40997 | 23600165 | 34 | 17441 | |||
| 2023-02-07 | 6-K | FORM 6-K | 0001062993-23-002395 | 001-40997 | 23596079 | 34 | 689962 | |||
| 2023-01-30 | 6-K | f6k-20230109drug.htm | 0001183740-23-000012 | 001-40997 | 23568346 | 34 | 13382 | |||
| 2023-01-27 | 6-K | f6k-20230127drug.htm | 0001183740-23-000009 | 001-40997 | 23564311 | 34 | 17483 | |||
| 2022-12-29 | 20-F | FORM 20-F | 0001062993-22-024547 | 001-40997 | 221499259 | 34 | 9359091 | 1 | 1 | |
| 2022-12-06 | 6-K | FORM 6-K | 0001062993-22-023349 | 001-40997 | 221446078 | 34 | 17541 | |||
| 2022-11-29 | 6-K | FORM 6-K | 0001062993-22-022863 | 001-40997 | 221427707 | 34 | 18571 | |||
| 2022-11-23 | 6-K | f6k-20221123drug.htm | 0001183740-22-000182 | 001-40997 | 221417140 | 34 | 19159 | |||
| 2022-09-14 | D | xslFormDX01/primary_doc.xml | 06b | 0001183740-22-000165 | 021-458931 | 221243794 | 33 | 10869 | ||
| 2022-09-08 | 6-K | f6k-20220907drug.htm | 0001183740-22-000164 | 001-40997 | 221233771 | 34 | 19642 | |||
| 2022-09-08 | 6-K | f6k-20220831drug.htm | 0001183740-22-000162 | 001-40997 | 221233768 | 34 | 20998 | |||
| 2022-09-01 | D | xslFormDX01/primary_doc.xml | 06b | 0001183740-22-000159 | 021-457729 | 221220649 | 33 | 11294 | ||
| 2022-08-30 | 6-K | f6k-20220830drug.htm | 0001183740-22-000158 | 001-40997 | 221215573 | 34 | 14598 | |||
| 2022-08-29 | 6-K | f6k-20220826drug.htm | 0001183740-22-000155 | 001-40997 | 221207001 | 34 | 1143617 | |||
| 2022-08-24 | 6-K | f6k-20220823drug.htm | 0001183740-22-000153 | 001-40997 | 221190770 | 34 | 18170 | |||
| 2022-08-23 | 6-K | f6k-20220822drug.htm | 0001183740-22-000149 | 001-40997 | 221188120 | 34 | 15932 | |||
| 2022-08-18 | 6-K | f6k-20220818drug.htm | 0001183740-22-000146 | 001-40997 | 221177554 | 34 | 10884 | |||
| 2022-08-15 | 6-K | FORM 6-K | 0001062993-22-017893 | 001-40997 | 221161959 | 34 | 647606 | |||
| 2022-05-16 | 6-K | FORM 6-K | 0001062993-22-012649 | 001-40997 | 22930947 | 34 | 645265 | |||
| 2022-05-12 | 6-K | f6k-20220512drug.htm | 0001183740-22-000111 | 001-40997 | 22917582 | 34 | 25865 | |||
| 2022-05-03 | D | xslFormDX01/primary_doc.xml | 06b | 0001183740-22-000098 | 021-444201 | 22885689 | 33 | 11804 | ||
| 2022-05-03 | D | xslFormDX01/primary_doc.xml | 06b | 0001183740-22-000097 | 021-444200 | 22885673 | 33 | 11803 | ||
| 2022-05-02 | 6-K | f6k-20220502drug.htm | 0001183740-22-000092 | 001-40997 | 22881373 | 34 | 26950 | |||
| 2022-04-19 | 6-K | f6k-20220419drug.htm | 0001183740-22-000086 | 001-40997 | 22834873 | 34 | 19391 | |||
| 2022-03-14 | 6-K | f6k-20220314drug.htm | 0001183740-22-000063 | 001-40997 | 22736622 | 34 | 18445 | |||
| 2022-03-08 | 6-K | f6k-20220308drug.htm | 0001183740-22-000059 | 001-40997 | 22721398 | 34 | 19113 | |||
| 2022-03-02 | 6-K | f6k-20220301drug.htm | 0001183740-22-000047 | 001-40997 | 22700470 | 34 | 676076 | |||
| 2022-02-15 | 6-K | FORM 6-K | 0001062993-22-004353 | 001-40997 | 22636548 | 34 | 617600 | |||
| 2022-01-18 | 20-F/A | FORM 20-F/A | 0001062993-22-001182 | 001-40997 | 22535694 | 34 | 6350702 | 1 | 1 | |
| 2022-01-05 | 6-K | f6k-20220104drug.htm | 0001183740-22-000002 | 001-40997 | 22508385 | 34 | 18351 | |||
| 2021-12-29 | 20-F | FORM 20-F | 0001062993-21-013611 | 001-40997 | 211528759 | 34 | 2405775 | 1 | 1 | |
| 2021-11-30 | 6-K | f6k-20211130drug.htm | 0001183740-21-000299 | 001-40997 | 211458941 | 34 | 21307 | |||
| 2021-11-04 | CERT | 8A CERT | 0001354457-21-001291 | 001-40997 | 211379697 | 34 | 185055 | |||
| 2021-11-03 | 6-K | f6k-20211103drug.htm | 0001183740-21-000281 | 001-40997 | 211374417 | 34 | 28336 | |||
| 2021-11-02 | 8-A12B | FORM 8-A12B | 0001062993-21-010071 | 001-40997 | 211368482 | 34 | 12996 | |||
| 2021-10-19 | 6-K | FORM 6-K | 0001062993-21-009705 | 000-56296 | 211330346 | 34 | 12691 | |||
| 2021-09-27 | 6-K | FORM 6-K | 0001062993-21-008947 | 000-56296 | 211282725 | 34 | 25553 | |||
| 2021-09-27 | UPLOAD | filename1.pdf | 0000000000-21-011744 | 39862 | ||||||
| 2021-09-17 | 6-K | FORM 6-K | 0001062993-21-008705 | 000-56296 | 211259160 | 34 | 560769 | |||
| 2021-09-17 | 6-K | FORM 6-K | 0001062993-21-008689 | 000-56296 | 211259080 | 34 | 15936 | |||
| 2021-09-17 | 20FR12G/A | FORM 20FR12G/A | 0001062993-21-008685 | 000-56296 | 211259073 | 34 | 1413213 | |||
| 2021-09-16 | CORRESP | filename1.htm | 0001062993-21-008687 | 15379 | ||||||
| 2021-09-15 | UPLOAD | filename1.pdf | 0000000000-21-011200 | 44626 | ||||||
| 2021-08-27 | CORRESP | filename1.htm | 0001062993-21-007990 | 18434 | ||||||
| 2021-08-27 | 20FR12G/A | FORM 20FR12G/A | 0001062993-21-007988 | 000-56296 | 211214254 | 34 | 1411484 | |||
| 2021-08-24 | UPLOAD | filename1.pdf | 0000000000-21-010384 | 44839 | ||||||
| 2021-08-18 | 6-K | FORM 6-K | 0001062993-21-007717 | 000-56296 | 211187538 | 34 | 19756 | |||
| 2021-08-13 | CORRESP | filename1.htm | 0001062993-21-007435 | 23938 | ||||||
| 2021-08-13 | 20FR12G/A | FORM 20FR12G/A | 0001062993-21-007433 | 000-56296 | 211169814 | 34 | 1415874 | |||
| 2021-08-04 | UPLOAD | filename1.pdf | 0000000000-21-009590 | 46023 | ||||||
| 2021-07-29 | 20FR12G/A | FORM 20FR12G/A | 0001062993-21-006791 | 000-56296 | 211124443 | 34 | 1636959 | |||
| 2021-07-28 | CORRESP | filename1.htm | 0001062993-21-006793 | 50141 | ||||||
| 2021-07-16 | UPLOAD | filename1.pdf | 0000000000-21-008829 | 59354 | ||||||
| 2021-06-25 | D | xslFormDX01/primary_doc.xml | 06b | 0001183740-21-000131 | 021-404247 | 211044347 | 33 | 11780 | ||
| 2021-06-17 | 20FR12G | FORM 20FR12G | 0001062993-21-005781 | 000-56296 | 211025689 | 34 | 4113512 | |||
| 2021-05-04 | D | xslFormDX01/primary_doc.xml | 06b | 0001183740-21-000097 | 021-398178 | 21887827 | 33 | 10806 | ||
| 2021-03-23 | D | xslFormDX01/primary_doc.xml | 06b | 0001183740-21-000060 | 021-393110 | 21762601 | 33 | 11346 | ||
| 2020-11-17 | D | xslFormDX01/primary_doc.xml | 06b | 0001183740-20-000249 | 021-380780 | 201320355 | 33 | 11232 | ||
| 2020-11-17 | D | xslFormDX01/primary_doc.xml | 06b | 0001183740-20-000248 | 021-380778 | 201320308 | 33 | 10820 | ||
| 2020-10-07 | D | xslFormDX01/primary_doc.xml | 06b | 0001183740-20-000216 | 021-377277 | 201227659 | 33 | 7253 | ||
| 2020-10-06 | D | xslFormDX01/primary_doc.xml | 06b | 0001183740-20-000215 | 021-377274 | 201227562 | 33 | 7326 |
One latest value per concept from companyfacts (77 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 4.52M | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ffd | NetFeeAmt | NetFeeAmt | USD | 24,472.45 | 2026-08-12 | S-8 | 2026-08-13 | 0001062993-26-004235 | |||
| ffd | TtlFeeAmt | TtlFeeAmt | USD | 24,472.45 | 2026-08-12 | S-8 | 2026-08-13 | 0001062993-26-004235 | |||
| ffd | TtlOfferingAmt | TtlOfferingAmt | USD | 177.21M | 2026-08-12 | S-8 | 2026-08-13 | 0001062993-26-004235 | |||
| ffd | TtlOffsetAmt | TtlOffsetAmt | USD | 0 | 2026-08-12 | S-8 | 2026-08-13 | 0001062993-26-004235 | |||
| ifrs-full | AccountingProfit | AccountingProfit | CAD | -2.80M | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | AccrualsClassifiedAsCurrent | AccrualsClassifiedAsCurrent | CAD | 41,751 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ifrs-full | AdditionsToRightofuseAssets | AdditionsToRightofuseAssets | CAD | 124,506 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | AdjustedWeightedAverageShares | AdjustedWeightedAverageShares | shares | 4.31M | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | AdjustmentsForDecreaseIncreaseInPrepaidExpenses | AdjustmentsForDecreaseIncreaseInPrepaidExpenses | CAD | -188,936 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables | AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables | CAD | 0 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | AdjustmentsForDepreciationAndAmortisationExpense | AdjustmentsForDepreciationAndAmortisationExpense | CAD | 73,357 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill | AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill | CAD | 0 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | AdjustmentsForIncreaseDecreaseInTradeAccountPayable | AdjustmentsForIncreaseDecreaseInTradeAccountPayable | CAD | 241,992 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | AdjustmentsForSharebasedPayments | AdjustmentsForSharebasedPayments | CAD | 839,771 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | AdjustmentsForUnrealisedForeignExchangeLossesGains | AdjustmentsForUnrealisedForeignExchangeLossesGains | CAD | -10,126 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | ApplicableTaxRate | ApplicableTaxRate | pure | 0.26 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | Assets | Assets | CAD | 6.10M | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ifrs-full | BasicAndDilutedEarningsLossPerShare | BasicAndDilutedEarningsLossPerShare | CAD/shares | -0.96 | 2020-10-01 | 2021-09-30 | 2021 | FY | 20-F/A | 2022-01-18 | 0001062993-22-001182 |
| ifrs-full | BasicEarningsLossPerShare | BasicEarningsLossPerShare | CAD/shares | -0.65 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | CashAndCashEquivalents | CashAndCashEquivalents | CAD | 5.72M | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ifrs-full | CashFlowsFromUsedInFinancingActivities | CashFlowsFromUsedInFinancingActivities | CAD | 810,572 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | CashFlowsFromUsedInOperatingActivities | CashFlowsFromUsedInOperatingActivities | CAD | -1.85M | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | CashOutflowForLeases | CashOutflowForLeases | CAD | 89,730 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | CurrentAssets | CurrentAssets | CAD | 5.99M | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ifrs-full | CurrentLeaseLiabilities | CurrentLeaseLiabilities | CAD | 79,384 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ifrs-full | CurrentLiabilities | CurrentLiabilities | CAD | 528,683 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ifrs-full | CurrentPrepaidExpenses | CurrentPrepaidExpenses | CAD | 216,628 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ifrs-full | CurrentTaxAssetsCurrent | CurrentTaxAssetsCurrent | CAD | 50,224 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ifrs-full | DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised | DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised | CAD | 0 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ifrs-full | DepreciationRightofuseAssets | DepreciationRightofuseAssets | CAD | 73,357 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | DilutedEarningsLossPerShare | DilutedEarningsLossPerShare | CAD/shares | -0.65 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | DirectorsRemunerationExpense | DirectorsRemunerationExpense | CAD | 493,793 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | EffectOfExchangeRateChangesOnCashAndCashEquivalents | EffectOfExchangeRateChangesOnCashAndCashEquivalents | CAD | 11,720 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | Equity | Equity | CAD | 5.54M | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ifrs-full | EquityAndLiabilities | EquityAndLiabilities | CAD | 6.10M | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ifrs-full | ExpenseByNature | ExpenseByNature | CAD | 2.83M | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets | ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets | CAD | 839,771 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | ExpenseFromSharebasedPaymentTransactionsWithEmployees | ExpenseFromSharebasedPaymentTransactionsWithEmployees | CAD | 880,615 | 2020-10-01 | 2021-09-30 | 2021 | FY | 20-F/A | 2022-01-18 | 0001062993-22-001182 |
| ifrs-full | GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss | GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss | CAD | -9,312 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | GeneralAndAdministrativeExpense | GeneralAndAdministrativeExpense | CAD | 264,009 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill | ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill | CAD | 0 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | IncomeTaxExpenseContinuingOperations | IncomeTaxExpenseContinuingOperations | CAD | 0 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | IncreaseDecreaseInCashAndCashEquivalents | IncreaseDecreaseInCashAndCashEquivalents | CAD | -1.04M | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | IncreaseDecreaseInNumberOfSharesOutstanding | IncreaseDecreaseInNumberOfSharesOutstanding | shares | 4.05M | 2019-07-01 | 2019-07-31 | 2021 | FY | 20-F/A | 2022-01-18 | 0001062993-22-001182 |
| ifrs-full | IncreaseDecreaseThroughExerciseOfWarrantsEquity | IncreaseDecreaseThroughExerciseOfWarrantsEquity | CAD | 253,440 | 2022-10-01 | 2023-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets | IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets | CAD | 96 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | IncreaseDecreaseThroughSharebasedPaymentTransactions | IncreaseDecreaseThroughSharebasedPaymentTransactions | CAD | 839,771 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | IntangibleAssetsAndGoodwill | IntangibleAssetsAndGoodwill | CAD | 0 | 2022-09-30 | 2022 | FY | 20-F | 2022-12-29 | 0001062993-22-024547 | |
| ifrs-full | InterestExpenseOnLeaseLiabilities | InterestExpenseOnLeaseLiabilities | CAD | 8,945 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | IssuedCapital | IssuedCapital | CAD | 35.42M | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ifrs-full | KeyManagementPersonnelCompensation | KeyManagementPersonnelCompensation | CAD | 1.27M | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | KeyManagementPersonnelCompensationSharebasedPayment | KeyManagementPersonnelCompensationSharebasedPayment | CAD | 493,793 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | LeaseLiabilities | LeaseLiabilities | CAD | 118,960 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ifrs-full | Liabilities | Liabilities | CAD | 568,259 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ifrs-full | NoncurrentLeaseLiabilities | NoncurrentLeaseLiabilities | CAD | 39,576 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ifrs-full | OtherCurrentReceivables | OtherCurrentReceivables | CAD | 0 | 2023-09-30 | 2023 | FY | 20-F | 2023-12-29 | 0001062993-23-023281 | |
| ifrs-full | OtherReserves | OtherReserves | CAD | 4.01M | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ifrs-full | PaymentsForShareIssueCosts | PaymentsForShareIssueCosts | CAD | 0 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities | PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities | CAD | 89,730 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | ProceedsFromIssueOfOrdinaryShares | ProceedsFromIssueOfOrdinaryShares | CAD | 80,980 | 2019-10-07 | 2020-09-28 | 2021 | FY | 20-F/A | 2022-01-18 | 0001062993-22-001182 |
| ifrs-full | ProceedsFromIssuingOtherEquityInstruments | ProceedsFromIssuingOtherEquityInstruments | CAD | 900,000 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | ProceedsFromIssuingShares | ProceedsFromIssuingShares | CAD | 27.74M | 2020-10-01 | 2021-09-30 | 2021 | FY | 20-F/A | 2022-01-18 | 0001062993-22-001182 |
| ifrs-full | ProfessionalFeesExpense | ProfessionalFeesExpense | CAD | 547,765 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | ProfitLoss | ProfitLoss | CAD | -2.80M | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | ResearchAndDevelopmentExpense | ResearchAndDevelopmentExpense | CAD | 1.18M | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | RetainedEarnings | RetainedEarnings | CAD | -34.35M | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ifrs-full | RevenueFromInterest | RevenueFromInterest | CAD | 30,133 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | RightofuseAssets | RightofuseAssets | CAD | 117,658 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ifrs-full | SalesAndMarketingExpense | SalesAndMarketingExpense | CAD | 41,600 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | ShareIssueRelatedCost | ShareIssueRelatedCost | CAD | 26,976 | 2022-10-01 | 2023-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | TaxExpenseIncomeAtApplicableTaxRate | TaxExpenseIncomeAtApplicableTaxRate | CAD | -727,974 | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |
| ifrs-full | TradeAndOtherCurrentPayables | TradeAndOtherCurrentPayables | CAD | 449,299 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ifrs-full | TradeAndOtherCurrentPayablesToRelatedParties | TradeAndOtherCurrentPayablesToRelatedParties | CAD | 61,061 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ifrs-full | TradeAndOtherCurrentPayablesToTradeSuppliers | TradeAndOtherCurrentPayablesToTradeSuppliers | CAD | 407,548 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ifrs-full | WarrantReserve | WarrantReserve | CAD | 455,573 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 | |
| ifrs-full | WeightedAverageShares | WeightedAverageShares | shares | 4.31M | 2023-10-01 | 2024-09-30 | 2024 | FY | 20-F | 2024-12-31 | 0001062993-24-021301 |